title: Vascular protecting effect of angiotensin receptor blocker (ARB) on the radial artery graft.
abstract: OBJECTIVE
  We hypothesized that the vascular protecting effect of an angiotensin receptor blocker (ARB) reduced endothelial damage of the radial artery (RA) after coronary bypass and conducted a comparative study.
  
  
  METHODS
  One hundred and sixty four patients were divided into the following two groups, Group C: 92 subjects who were orally administered Candesartan 8 mg/day, Group I: 72 subjects who were administered Imidapril at 5 mg/day. Graft angiography was performed one year after surgery and the RA intima was evaluated using an angioscope.
  
  
  RESULTS
  Total cholesterol of Group C was 151.4+/-66.9 mg/dL, which was significantly lower than in Group I (182.2+/-27.8 mg/dL), and LDL cholesterol of the ARB-treated group, i.e., Group C was 96.1+/-32.5 mg/dL and significantly lower than in Group I (139.1+/-48.7 mg/dL). In angioscopy, yellow plaque was detected in the proximal RA in 7 (8.0%) and 8 (11.6%) patients of the Groups C and I, respectively, showing a lower tendency in the ARB-treated group.
  
  
  CONCLUSIONS
  The results of evaluation one year after surgery revealed no significant difference in effects on the RA endothelium between ARB and ACE inhibitor. ARB reduced cholesterol and its effect was confirmed with blood examination data and endoscopic findings.
authors.affiliation: Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Mitsumasa
authors.initials: M
authors.lastname: Hata
authors.forename: Akira
authors.initials: A
authors.lastname: Sezai
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Niino
authors.forename: Masataka
authors.initials: M
authors.lastname: Yoda
authors.forename: Tadateru
authors.initials: T
authors.lastname: Takayama
authors.forename: Akiko
authors.initials: A
authors.lastname: Takemoto
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Himi
authors.forename: Motomi
authors.initials: M
authors.lastname: Shiono
authors.forename: Nanao
authors.initials: N
authors.lastname: Negishi
authors.forename: Kazutomo
authors.initials: K
authors.lastname: Minami
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017546:Angioscopy; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D001562:Benzimidazoles / Q000008:administration & dosage*; D001713:Biphenyl Compounds; D017023:Coronary Angiography; D001026:Coronary Artery Bypass / Q000379:methods*; D005260:Female; D006801:Humans; D048289:Imidazolidines / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D017534:Radial Artery / Q000637:transplantation*; D013777:Tetrazoles / Q000008:administration & dosage*; D014654:Vascular Patency / Q000187:drug effects
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D048289:Imidazolidines; D013777:Tetrazoles; C065166:imidapril; C081643:candesartan